Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) shares were down 0.4% on Thursday . The stock traded as low as $7.80 and last traded at $7.99. Approximately 815 shares changed hands during trading, a decline of 74% from the average daily volume of 3,077 shares. The stock had previously closed at $8.0250.
Clinuvel Pharmaceuticals Trading Down 0.4%
The business has a 50-day moving average price of $8.22 and a 200-day moving average price of $7.85.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
See Also
- Five stocks we like better than Clinuvel Pharmaceuticals
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- When to buy gold (mathematically)
- NEW LAW: Congress Approves Setup For Digital Dollar?
- EXPOSED: The “29% Account”
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
